Profile of bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination and its potential in the treatment of HIV-1 infection: evidence to date

• Main Authors: Hill L, Smith SR, Karris MY
• Format: Article
• Language: English
• Published: Dove Medical Press 2018-10-01
• Series: HIV/AIDS : Research and Palliative Care
• Subjects: Biktarvy; HIV care; review; Integrase strand transfer inhibitor
• Online Access: https://www.dovepress.com/profile-of-bictegraviremtricitabinetenofovir-alafenamide-fixed-dose-co-peer-reviewed-article-HIV

Lucas Hill,1 Shawn R Smith,1 Maile Young Karris2 1University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, San Diego, CA, USA; 2Department of Medicine, University of California San Diego, San Diego, CA, USA Abstract: Modern pharmacologic management of people living with HIV involves the use of fixed dose combinations of antiretrovirals that are simple to take, well tolerated, and highly effective. Specific recent pharmacologic advancements include 1) the second-generation integrase strand transfer inhibitors (dolutegravir and bictegravir) that consistently show less side effects, high tolerability, minimal drug interactions, and rapid rates of HIV viral load decline and 2) tenofovir alafenamide, a prodrug of tenofovir that concentrates in lymphoid tissue and minimizes off target effects. Bictegravir/emtricitabine/tenofovir alafenamide or B/F/TAF is a recently approved fixed dose combination that incorporates these new advancements in the management of HIV. This review focuses on the data supporting the use of B/F/TAF, reviews clinically relevant findings, and highlights the unanswered questions that may limit its clinical utility. Keywords: Biktarvy, HIV care, review, integrase strand transfer inhibitor